Corcept Therapeutics Inc ($CORT) Feb 19 Update

Quick EN/IT follow-up after the U.S. Court of Appeals for the Federal Circuit upheld the New Jersey decision that Teva’s proposed generic Korlym does not infringe two Corcept patents, clearing a key legal hurdle for generic competition. We look at what this means for Korlym cash flows, how it interacts with the recent relacorilant CRL and why the ovarian cancer PDUFA remains the central medium-term catalyst.

Hims & Hers Health Inc ($HIMS)

A deep dive into Hims & Hers after the GLP-1 “pill gambit”, the Novo Nordisk lawsuit, and the transformative acquisition of Eucalyptus: business model, financials, balance sheet, insiders, retail crowd and key catalysts for 2026–2027

Red Cat Holdings, Inc.($RCAT)

RCAT has a small analyst following relative to larger defense primes, but those who do cover the name generally frame it as a high-risk, high-reward play on secure U.S. and allied drone demand. Consensus ratings tilt toward “buy” or “speculative buy” in many summaries, with target prices that imply substantial upside from depressed levels – but also embed assumptions about revenue ramp and contract wins that are far from guaranteed.

Ondas ($ONDS) eyes Aeronautics

Onds2026

Israeli business media report that Ondas has submitted an offer to buy Aeronautics, the unmanned systems subsidiary of Rafael. It is a proposal under review, not a completed acquisition. Below: what is confirmed, the political and regulatory risk, and how retail traders are reacting.

Geron Corp ($GERN) Feb 18 Update

Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO.

NRX Pharmaceuticals Inc ($NRXP)

NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue.

War Ai and the X Ecosystem

SpaceX launches satellites, Starlink keeps front lines online, X shapes the information space, and xAI’s Grok is being wired into military networks. A new Pentagon contest for voice-controlled autonomous drones shows how these pieces are starting to lock together into a single, highly political war-tech stack.

Castellum Inc ($CTM) Now Debt Free

From heavily leveraged roll-up to cash-rich, debt-free federal contractor: what changes after the last note payoff, how the Navy “Big 3” contracts reshape visibility, and what still can go wrong for shareholders.

ImmunityBio Inc ($IBRX) ANKTIVA in EU Ok!

European Commission Grants Final Conditional Marketing Authorization for ANKTIVA® in EU
Decision C(2026)1197: Final, binding authorization allowing commercial launch across 27 EU member states + Iceland, Norway, Liechtenstein for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Compass Pathways Plc ADR ($CMPS) Updated post CC

Release of new clinical data from two Phase 3 trials (COMP005 and COMP006) on COMP360 in TRD + management webcast
Tradable short-term event: additional clinical data (specific portions of studies) and official management narrative. This is the type of event that changes the perception of probability/quality of clinical evidence, and thus volatility too.

AI in Biotech 2026 $RXRX $TEM $EXAI

Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.

Precision Biosciences Inc ($DTIL)

Next catalyst
H1 2026 – Updated ELIMINATE-B Phase 1/2 data in chronic hepatitis B (PBGENE-HBV), including higher-dose biopsy readouts.
Secondary 2026 catalyst: first sites activated and initial multi-patient data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD after FDA IND clearance (Study May Proceed) in February 2026.

Aldeyra Therapeutics (ALDX) PDUFA March 2026

Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biotechnology company developing modulators of reactive aldehyde species (RASP) for immune-mediated and metabolic diseases. The key late-stage asset is reproxalap, an ophthalmic RASP modulator for dry eye disease (DED) and allergic conjunctiviti